Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain Aetiology

• Status: Unknown status
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Enalapril would significantly reduce progression of renal disease in patients with Chronic Kidney Disease of Uncertain aetiology.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ministry of Health, Sri Lanka
• Collaborator: World Health Organization
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Calcium; Calcium, Dietary; Enalapril; Enalaprilat; Enzyme Inhibitors

Criteria

Inclusion Criteria:

• Males and females between 18-70 years of age

• CKDu Grade 1, 2, 3

• No contraindication for treatment with ACEI

• Informed consent given

Exclusion Criteria:

• Grade 4 CKDu

• Other chronic diseases

• Evidence or suspicion of non renal secondary hypertension

• Diabetes type 1 or 2

• Evidence or suspicion of renovascular disease, obstructive uropathy, or other renal disease

• Treatment with corticosteroids, non-steroidal anti-inflammatory drugs, or immune-suppressive drugs

• Acute myocardial infarction or cerebrovascular accident in the previous 6 months

• Severe uncontrolled hypertension (diastolic blood pressure ≥115 and/or systolic blood pressure ≥220 mm Hg)

• Suspicion or evidence of connective tissue disease, cancer, higher serum aminotransferase concentrations

• Chronic cough; drug or alcohol abuse; pregnancy and breast feeding

• Unwillingness to sign informed consent